Antibodies News and Research

RSS

The chicken and egg problem of fighting another flu pandemic

Even a peep of news about a new flu pandemic is enough to set scientists clucking about eggs.

31 May 2024

Single infusion of engineered T-cells achieves lasting asthma remission in mice

Researchers demostrate that durable asthma remission can be achieved with engineered and long-lived CAR T-cell treatment in mice.

31 May 2024

Improved kidney transplant success from deceased donors with dialysis history

Researchers compare the outcomes of kidney transplants, in which the kidneys were from deceased donors who had or had not undergone dialysis.

31 May 2024

Engineered immunogens show promise in inducing HIV broadly neutralizing antibodies

Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs).

30 May 2024

Mast cells and PGE2: Key players in controlling asthma inflammation

Previous research indicates that mast cells, a type of immune cell found in the tissues throughout the body, cause inflammation during an asthma attack, inducing symptoms such as trouble breathing and narrowing of the airways.

30 May 2024

Newly discovered lincRNA controls the development and function of regulatory T cells

The T cells in our blood fight against cancer, viruses and bacteria. Specific regulatory T cells are required to control faulty immune responses, and disruption in their function may lead to autoimmune diseases or cancer.

30 May 2024

Exercise-induced exerkines: Secret weapon in disease prevention and therapy

A recent review in Signal Transduction and Targeted Therapy highlights the role of exercise-induced molecules, exerkines, in disease prevention and treatment, emphasizing their molecular mechanisms and therapeutic potential.

29 May 2024

New antibody shows promise as universal weapon against COVID-19 variants

SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions.

29 May 2024

New type of immunotherapy shows promising preclinical results against osteosarcoma

A new type of immunotherapy, developed by UCL researchers, has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice.

29 May 2024

Vaccination remains crucial for preventing avian influenza spread, says study

Vaccination remains the most effective strategy for avian influenza prevention and control in humans, despite varying vaccine efficacy across strains.

29 May 2024

Addressing local dynamics in rubella vaccination policy

When public health officials make policies about when and how vaccination programs are implemented, they must weigh the benefits and risks of how infectious diseases spread throughout the country.

29 May 2024

Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy

Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.

29 May 2024

Why use light scattering to analyze proteins and viral vectors?

n this interview, Dr. Michelle Chen, Senior Director of Analytical Sciences at Wyatt Technology, talks to NewsMedical about how to use light scattering techniques to analyze proteins for their multi-attribute quantification (MAQ).

From Waters | Wyatt Technology 29 May 2024

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

From Secarna Pharmaceuticals 29 May 2024